Home > Result Summaries: Compounds > Haemophilus influenzae Type b Vaccine > Result Summary for 213503/004

Result Summary for 213503/004

Result Summary

Protocol ID:	213503/004
Clinical Study ID:	213503/004
Official Title:	Immunogenicity and reactogenicity study of GSK’s combined diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, coadministered with GSK’s Haemophilus influenzae type b conjugate vaccine, either in 2 concomitant injections or mixed in one injection, given to healthy infants at 2, 4 and 6 months
Phase:	Phase 2/3
Study Indications or Diseases:	Diphtheria, Tetanus, Pertussis, Polio, Hib
Generic Name:	Haemophilus influenzae Type b Vaccine
Trade/Product Name:	Hiberix;Hiberix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Halperin SA et al. (1999) Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis. 28(5):995-1001.